Cancer Network spoke with Dr. Shishir Maithel about grading and diagnosing neuroendocrine tumors and how PRRT best fits into the treatment algorithm of these tumors.
Among patients with small-bowel neuroendocrine tumors, accurate lymph node staging may require the examination of at least eight lymph nodes.
An analysis of more than 70,000 patients revealed significant differences with regard to survival between different sites of origin for neuroendocrine tumors.
Lenvatinib offers the highest published response rate to a targeted agent for patients with advanced neuroendocrine tumors, but the agent’s precise role in this setting remains in question.
In general, NETs are considered an “immunological desert,” but a new study showed some promise for immunotherapy.
A retrospective analysis found that surgical resection and radiotherapy are linked to superior outcomes in patients with thymic neuroendocrine tumors.
Radioguided surgery using gallium 68 dota peptides offers a highly sensitive method for detecting neuroendocrine tumors.
For patients with NETs that have metastasized to the liver, high levels of serum pancreastatin are predictive of poor outcomes after treatment with TACE.
A new study suggests that the cytokine CXCL12 could be useful as a prognostic biomarker in patients with neuroendocrine tumors of the lung.
A study on pheochromocytoma and paraganglioma associated with neurofibromatosis type 1 highlights how screening for these malignancies is important.